CYBERDYNE

Consolidated Financial Result Briefing for the six months ended September 30, 2025

CYBERDYNE, Inc.
Nov 13, 2025

Consolidated financial statements

1H FY2025 - Consolidated Results Summary (IFRS)

Following 1Q, consolidated revenue decreased due to the impact of the sales of a subsidiary in the previous fiscal year, while operating profit improved
Profit before tax and profit attributable to owners of parent remained positive, mainly due to gains on valuation of investment securities

(Millions of yen)	2024/1H	2025/1H	YoY	%
Revenue	2,143	1,963	-179	-8.4%
Operating profit (loss)	(497)	(174)	+323	-
Profit (loss) before tax	(215)	297	+512	-
Profit (loss) attributable to owners of parent	(305)	70	+375	-

Revenue

1,963 Million
YoY -179 Million (-8.4%)

- EMEA product rentals: +107 million yen (business +108 million yen, forex –1 million yen)
- Domestic & APAC product rentals, etc.: +90 million yen (business +107 million yen, forex –16 million yen)
- Treatment services: –124 million yen (business –88 million yen, forex –37 million yen)
- New business expansion: LeyLine –220 million yen, domestic –32 million yen

Operating profit (loss)

-174 Million
YoY +323 Million

- EMEA product rentals: +78 million yen (business +79 million yen, forex –1 million yen)
- Domestic & APAC product rentals, etc.: +84 million yen (business +94 million yen, forex –10 million yen)
- Treatment services: +17 million yen (business +14 million yen, forex +2 million yen)
- New business expansion: LeyLine +153 million yen, domestic +23 million yen
- R&D and head office expenses, etc.: –31 million yen

Profit (loss) before tax

297 Million
YoY +512 Million

- Operating profit variance: +323 million yen
- Gain on valuation of investment securities: +178 million yen
  (FY2025 1H: +482 million yen vs. FY2024 1H: +305 million yen)
- Finance costs -89 million yen (FY2025 1H: -261 million yen vs. FY2024 1H: -173 million yen)
  FY2025 : Provision for doubtful accounts for LeyLine 252 million yen
- Others (Gains related to CEJ Fund, etc.): +11 million yen

※ Exchange Rate USD/JPY: Mar 149.52 → Sep 148.88 (YoY: Mar 151.41 → Sep 142.73)
EUR/JPY: Mar 162.08 → Sep 174.47 (YoY: Mar 163.24 → Sep 159.43)

Consolidated results: Revenue / Operating profit (Margin)

Product rentals and related services recorded year-on-year increases in both revenue and profit, driven by continued expansion in EMEA, APAC, and Japan

Treatment services recorded a decrease in revenue but an increase in profit, reflecting improved profitability at RHG in the U.S

New business expansion recorded a decrease in revenue but an increase in profit, mainly due to the impact of the LeyLine sale in the previous fiscal year

(Millions of yen)		2024/1H	2025/1H	YoY	%
Product rental	Revenue Operating Profit (Margin %)	832 333 (40%)	1,030 495 (48%)	+198 +162 (+8pt)	+24% +49%
Treatment service	Revenue Operating Profit (Margin %)	946 -62 (-7%)	822 -46 (-6%)	-124 +16 (+1pt)	-13% -
New business expansion	Revenue Operating Profit (Margin %)	365 -170 (-47%)	112 6 (6%)	-253 +176 (+53pt)	-69% -
R&D expenses & Head office expenses	Adjusted amount	-598	-630	-32	-
Consolidated total (IFRS)	Revenue Operating Profit (Margin %)	2,143 -497 (-23%)	1,963 -174 (-9%)	-179 +323 (+14pt)	-8% -

- Amount of operating profit or loss, which is revenue minus operating expenses, for each business
- Adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

- Product rental：Revenue from rental of the Group's products（includes revenue from sales)
- Treatment service：Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
- New business expansion：Revenue from the Group's new business (e.g. subsidiary in Mobility and Sleeping App)

Revenue from rental and sales (by product)

(Millions of yen) 2025/1H (2024/1H)	Japan	EMEA	APAC	AMER	Total	YoY
Product rental	488 (456)	245 (137)	277 (220)	20 (19)	1,030 (832)	+198 (+24%)
Treatment Service	62 (63)	33 (21)	-	726 (862)	822 (946)	-124 (-13%)
New business Expansion	112 (144)	- (220)	-	-	112 (365)	-253 (-69%)
Total	662 (663)	278 (379)	277 (220)	746 (880)	1,963 (2,143)	-179 (-8%)
YoY	-1 (-0%)	-101 (-27%)	+57 (+26%)	-136 (-15%)		
	Domestic	Foreign				
Sales Revenue ratio	34%	66%			100%	

EMEA :Europe, the Middle East and Africa
APAC : Asia-Pacific *Excluding Japan
AMER : North, Central and South America

Revenue from rental and sales (by product)

Domestic sales remained solid, supported by new installations of the Medical HAL Lower Limb Type and mobile robot

Overseas sales also remained strong, mainly in EMEA (primarily Germany) and APAC (primarily Malaysia).

(Millions of yen) 2025/1H (2024/1H)	Type of product	In Japan	Outside Japan	Total
Cybernics Treatment Functional improvement and regeneration	Medical HAL Lower Limb Type	210 (183)	385 (268)	595 (450)
	Non-medical HAL Lower Limb Type	76 (80)	-	76 (80)
	HAL Single Joint Type	48 (44)	75 (52)	123 (96)
Well-being and care	HAL Lumbar Type	40 (51)	58 (43)	98 (95)
Labor Support	HAL Lumbar Type	18 (19)	-	18 (19)
	Mobile robot (CL02 etc.)	51 (39)	-	51 (39)
Other（Acoustic X、Other products）		45 (41)	24 (13)	69 (54)
Total		488 (456)	542 (376)	1,030 (832)

Business Policy and Initiatives for Business Growth

Realization of “Techno-peer Support Society”

A future society where people and technology coexists, cooperates and mutually support each other

For wide variety of people faced with health, physical function, cognitive and psychological problems
A safe and secure society (well-being society) where people of all generations can increase their independence, freedom and solve various problems in their lives



→ Create “Cybernics Industry”, a new industry that follows Robot and IT Industry

Cybernics Technology: Innovative core technology of Cybernics Industry

Cybernics: Fuses and combines humans, AI-Robots and Information Systems



***Cybernics:** Science and technology in cutting-edge areas that combine different fields such as brain/neuroscience, physiology, artificial intelligence (AI), robotics, information technology (IT), psychology, economy and innovation with a focus on Human, AI-robots and Information Systems to realize the fusion of bio/medical technologies and AI, robotics and information technologies.

(Reference)
The Cabinet Office's FIRST, ImPACT, and SIP programs address Cybernics as pioneering cutting-edge innovative science and technology areas

Business development centered on Cybernics medical health and life innovation in the integrated space of “Human” + “Cyber/Physical Space”

Improving the well-being of seniors and people with disability



Improving the well-being through supporting and supervising solutions

Towards the 5th Industrial Revolutions!
“Human”+”Cyber/Physical Space”

HCPS Fusion Technology Cybernics Industry

that will follow Robot and IT Industry



Prevention, early detection and medical/healthcare



Work support and improving efficiency through AI automation



Future of medical healthcare and healthy life
Prevention/early detection, medicine, rehabilitation/long-term care

Medical/Healthcare/Healthy life

Pre-Hospital
Early medical・life period Prevent/early detection

Hospital
Diagnose, treat, inpatient/outpatient

Post-Hospital
Late medical・life period : rehab/long-term care

early medical・life period

Acute

Recovery

Late medical・life period

Household・work place・life space

Household・work place・life space



Close coordination, fusion between medical and non-medical field to evolve into comprehensive initiatives

Wearable cyborg HAL®

HAL® identified as the only device that induces neuroplasticity and provides comprehensive therapeutic effects — published in an international medical journal (comparison with passively controlled exoskeleton-type devices)



Review Article

AO SPINE

Actively Controlled Exoskeletons Show Improved Function and Neuroplasticity Compared to Passive Control: A Systematic Review

Global Spine Journal
2025, Vol. 15(8) 3933–3952

DOI: 10.1177/21925682251343529
journals.sagepub.com/home/gsj
Sage

A systematic review analyzed 27 clinical studies selected from 555 publications released over a 12-year period, providing one of the highest levels of scientific evidence.

Ka Ioi Argu
James Gedd
and Darren

Abstract

Study Design: Systematic Review.

Objectives: To determine whether actively controlled exoskeletons or passively controlled exoskeletons are better at rehabilitating patients with SCIs.

Methods: A literature search between January 2011 to June 2023 on Pubmed Central, Pubmed, Web of Science and Embase was carried out. Exoskeletons were classified as actively controlled if they detect bioelectrical signals (HAL). All other exoskeletons were classified as passively controlled (ReWalk, Ekso, H-MEX, Atlante, Indego, Rex Bionics, SuitX Phoenix, Lokomat and HANK). Functional outcomes used were 6 minute walk test (6MWT) distance and 10 metre walk test (10MWT) speed. Further subgroup analysis was carried out for acute and chronic SCI patients. All outcomes were examined without the aid of the exoskeleton device. Secondary outcomes including continence, pain and quality of life were also examined.

Results: 555 articles were identified in the initial search and 27 were included in the review resulting in a total of 591 patients and 10 different exoskeleton models. HAL was the only exoskeleton to show improvements in both mobility and all secondary health outcomes. HANK and Ekso also showed improvements in mobility. Rewalk showed improvements in all secondary health outcomes with Ekso only showing improvements in QoL. No other exoskeletons showed significant improvements.

Conclusion: In conclusion, the actively controlled exoskeleton HAL showed improvement in all outcomes of interest suggesting that neuroplasticity could be induced with HAL rehabilitation allowing the weakened bioelectrical signals to transcend the SCI to show genuine improvements.

In this review, HAL® was compared with nine other passively controlled exoskeleton-type devices (devices that repeatedly perform movements through robotic control). The results clearly demonstrated that only HAL® induces neuroplasticity and provides comprehensive therapeutic effects across multiple health outcomes associated with spinal cord injury (SCI).

The paper discusses that the repetitive neuromuscular process established between the central and peripheral nervous systems—made possible by HAL®'s core principles—facilitates the learning and reinforcement of neural signaling in the brain and spinal cord. This process ultimately leads to the reconstruction and reactivation of spinal circuits below the site of spinal cord injury and the partial reinnervation of neural pathways.

Through this mechanism of inducing neuroplasticity, HAL® demonstrated consistent improvements not only in primary mobility functions such as walking ability but also in secondary health indicators, including urinary and bowel function (continence), pain reduction, and overall quality of life (QoL).

HAL Elicits Neuroplasticity in the Brain

Cerebral evidence supports that HAL® directly engages the user's central nervous system

2322 IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING, VOL. 33, 2025

Cerebral Correlates of Robot-Assisted Upper Limb Motion Driven by Motor Intention in Healthy Individuals: An fNIRS Study

Margaux Noémie Lafitte, Christina Sylvia Andrea, Hideki Kadone, Eiichi Hoshino, Masashi Yamazaki, Yasuyo Minagawa, and Kenji Suzuki, *Senior Member, IEEE*

***Abstract*— The past few years have seen an exponential growth of the robot-assisted rehabilitation field and new technological developments allowing the integration of the user's intention through detection of physiological information. The inclusion of motor intention is thought to be promising for motor rehabilitation and to facilitate neuroplasticity potentially by stimulating the cortical circuitry more than, or at least differently from, non-voluntary passive motion. Yet, contrasting results are reported in the literature. We aimed here to investigate the importance of the integration of motor intention on cortical activity using functional near-infrared spectroscopy (fNIRS) by comparing the active use of an assistive exoskeleton targeting the shoulder with passive use and unassisted motion. We recorded the activity of the bilateral frontal and parietal cortices of 20 healthy individuals during an arm raising task. Active robot assistance showed similar activity patterns to unassisted motion with the exception of a greater activation of the prefrontal region. Correlates of intention could be confirmed by an activation of the supplementary motor area in active-assisted and unassisted but not passive condition. Activation of the contralateral primary sensorimotor regions did not differ between passive and active conditions but activity of the ipsilateral hemisphere and secondary regions was reduced during passive motion. Our results provide arguments in favor of the integration of the user's intention through physiological signals for rehabilitation, in favor of the investigation of secondary and ipsilateral regions, and in favor of the use of fNIRS to investigate differences in cortical correlates of passive and active motion.**

***Index Terms*— Cortical activity, functional near-infrared spectroscopy (fNIRS), robot-assisted rehabilitation, shoulder motion, voluntary intention.**

I. Introduction

IN THE past few years, the field of robot-assisted rehabilitation has seen exponential growth owing to technical improvements and the publication of promising results. It presents several advantages compared to typical rehabilitation approaches: it reduces the burden on therapists, offers high repeatability, repetition, and intensity, and it is thought to be more compelling for patients [1], [2], [3]. A subclass of the field is active assistance, which incorporates the intention of the patient, allowing voluntary training. If different control methods and ways to integrate the user's intention have been proposed (among which force sensors, position sensors,

Brain activity during upper-limb motion with the wearable cyborg HAL® was visualized and quantified using functional near-infrared spectroscopy (fNIRS).

This study confirmed that, during motion assisted by HAL®, higher-order motor areas in the brain were significantly activated in synchrony with the wearer's voluntary motor intention.

These findings demonstrate that HAL® activates cortical regions associated with voluntary movement and suggest its potential to induce neuroplasticity in the brain. This provides scientific evidence supporting HAL®'s therapeutic mechanism, which promotes functional improvement and regeneration of the nervous and muscular systems.

Note: One of the authors of this study, Professor Kenji Suzuki of the University of Tsukuba, serves as an outside director of the Company and has certain economic interests in the Company.

【Prevention/Early detection, Diagnosis check】Super small vital sensor “Cyvis”

Cyvis M100 : Approved as a medical device in Japan (Nov,2024)

Compact Holter electrocardiograph
Medical vital sensor
Cyvis M100

- **Long-term continuous**
  ECG measurement for approximately 10 days on a single charge
- **No data extraction required**
  Data is automatically saved to a secure cloud via smartphones or tablets,
  enabling remote access to data
- **electable electrodes**
  Original gel electrodes that can be easily applied
  Compatible with commercially available single-use ECG electrodes
- **Simultaneous measurement of various data**
  - Acceleration (body movement), angle
  - Skin surface temperature
  - Clothing temperature, humidity, and air pressure

【Prevention/Early detection, Diagnosis check】Super small vital sensor “Cyvis”

One device to accumulate, analyze and AI process various vital data

Application of Cyvis



【Prevention and early detection】Ultra small vital sensor Cyvis

Expands remote service that connects households to hospitals and facilities



Contrast-free, non-invasive, real-time, high-resolution 3D imaging

LED array method (patent held by CYBERDYNE)

Adopted as the cover of BioPhotonics, a U.S. industry journal dealing with biophotonics



Peripheral vascular and blood conditions, etc.

Peripheral level examination, which could not be done with conventional imaging equipment, is now possible!

Example of application

- Routine examination and diagnosis of diabetic foot lesions
- Examination of vascular regeneration status by regenerative medicine
- Examination and diagnosis of cancer
- Examination of aging skin, etc.

Currently promoting medical device commercialization as a next-generation medical diagnostic imaging device

Research and Development

HCPS fusion technology：Cybernics/Human cooperative robotics

As a commitment to science, technology and innovation, CYBERDYNE participated in the Cabinet Office Strategic Innovation Creation Program (SIP) to strengthen growth strategies



1) Application to various living spaces such as houses, facilities, workplaces, etc.
2) Utilization of HCPS fusion master/remote control technology (Cybernic master/remote technology) integrated with human information (physiology, body, behavioral cognition, psychology, etc.)
3) Non-invasive acquisition and utilization of human information through HCPS fusion human collaborative robotics
4) Linking with other related technologies to improve the independence and freedom of seniors and people with mobility problems

Source: Cabinet Strategic Innovation Program (SIP), Secretariat of Science, Technology and Innovation, Cabinet Office, Government of Japan, “Development of Fundamental Technologies and Rules for Expanding Human-Coordinated Robotics: Strategy and R&D Plan for Social Implementation,” Pg 5.

Exhibition of “Future Me” at Expo 2025 Osaka, Kansai Demonstration at the Pasona Pavilion

- **“Me with Restored Physical Function”** **(Wearable Cyborg Technology — HAL®)**
- **“Me with an Expanded Living Environment”** **(Cybernics Master Remote Robot — enabling remote interaction and operation in daily life)**
- **“Me Being Safely Monitored”** **(Compact vital sensors and peripheral vascular imaging technology that continuously monitor physiological and motor information in everyday settings)**

Cybernics Master Remote Robot

Driving the Social Implementation of Physical AI through HCPS Integration

次世代ロボ、派遣業務担う

サイバーダイン、パソナと開発へ

装着型ロボット開発のCYBERDYNE（サイバーダイン）はパソナグループと組んで、人材派遣に活用できる次世代型ロボット開発に乗り出す。ひとの動きを遠隔操作でリアルタイムで忠実に再現する新型リモートロボを活用。一人で複数のロボを操作して省力化できる点を生かし、複数のロボに同時に複数の場所で作業させるなどして人手不足の解消や人材派遣コスト削減につなげる。

2月中旬、東京・南青山のパソナグループ本社で開いたサイバーダインの大阪・関西万博パソナ館への出展発表会で、同社の山海嘉之社長は「パソナはロボットを派遣する企業になりうる」と発言。サイボーグ型ロボットを人材派遣に活用する構想を明

ム」は、オペレ
遠隔操作で動く
グループ本社）

1人で複数操作

人手不足解消・コスト削減

ム」は、ひとの腕や指に装着したセンサーの動きをインターネット回線や高速大容量通信回線「5G」などでロボットに伝達。遠隔地にいるロボットをひとの動きに合わせて忠実に動かせる。

ロボットには4本の指と同様の関節を持ち、ものをかんだり、手放したりできる。「4本指でも（山海社長）といい、料のボトルの蓋を開けるなど、微妙な力加減が要な動きもこなす。レーターは、ロボット装着したカメラを通し見える空間を「拡張現（AR）ゴーグル」を して把握しながら操る。

サイバーダインが した自律走行しなが 港などの施設を自動 除するロボットの仕

Feb 27, 2025 Nikkei

Clinical Development

Medical device approval for Medical HAL Lower Limb Type

Small size approved in Japan, the US, and Europe

As of September 30, 2025

		Stroke	Spinal Cord Injury	Neuromuscular Disease*	Other diseases	Small size
Japan		(Preparing for additional trial)	(Communicating with regulators)	Approved	• HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
USA		Approved	Approved	Approved	• Cerebral palsy • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
EMEA	Europe	Approved	Approved	Approved		Approved
	Türkiye	Approved	Approved	Approved		
	Saudi Arabia	Approved	Approved	Approved		
APAC	Malaysia	Approved	Approved	Approved		
	Indonesia	Approved	Approved	Approved		
	Thailand	Approved	Approved	Approved		
	Singapore	Approved	Approved	Approved		
	India	Approved	Approved	Approved		
	Taiwan	(application in progress)	Approved	(application in progress)		
	Australia	Approved	Approved	Approved		

*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

Clinical Development Pipeline

As of September 30, 2025

	Target disease	Product Development	Clinical Trial (Exploratory)	Clinical Trial (Validation)	Application/ examination	Approval (public health insurance in Japan)	Marketing (Post-marketing surveillance)	Public health insurance	Current status
Lower Limb	Neuromuscular Disease (8 types of disease such as ALS and muscular dystrophy)								FY2022 revision (DPC calculation) Planning for public health insurance Planning for insurance reimbursement
	Spinal related disease (2 diseases virus and hereditary)								Public health insurance approved Applying for expansion of target diseases Obtained medical device clearance
	Spinal Cord Injury							Public workers Compensation insurance (Germany)	Communicating with regulators Preparing trial towards public health insurance (Germany) Planning for insurance reimbursement
	Stroke								Preparing for additional clinical trial Planning for public health insurance Planning for insurance reimbursement
Lumbar	Parkinsons Disease								Preparing for clinical trial

2024/5
US FDA clears three additional diseases
- **HTLV-1 Associated Myelopathy (HAM)**
- **Hereditary Spastic Paraplegia**
- **Cerebral Palsy***

*Above 12 years old

Preparing additional trials (clinical trials) based on the latest patient profiles and clinical needs

Preparing clinical trials for Lumbar type based on favorable results from pilot trials

Social implementation of Cybernics Treatment in Germany

Clinical trials to be conducted on the premise of German public medical insurance coverage

G-BA (German Federal Joint Committee) decides to conduct clinical trials under the premise of insurance coverage

G-BA approves Cybernics Treatment as the standard of care to be considered for spinal cord injury patients (in accordance with §137eSGB V of the Study Regulations)

G-BA itself decides to conduct a clinical trial (the clinical trial will be covered by public health insurance for Cybernics Treatment in advance).

The results of the clinical trial are expected to be included in the German public medical insurance system.

G-BA Preparing Clinical Trials (currently selecting clinical trial facilities)

2023/01 Protocol outline presented

2023/03 Expert hearing held

2023/09 Protocol guideline announced

2024/11 CRO selection completed

G-BA (Federal Joint Committee): Organization at the federal level that determines basic benefits, prices, standards, etc. for German insurance treatment.
§137e SGB V (Trial Regulation): A system under which the G-BA conducts its own initiated clinical trials and makes final evaluations of promising treatments that could become the standard of care.

【Medical】Global Dissemination of Cybernics Treatment

Strategy to promote Cybernics as a global platform

Strengthening cooperation with politics/government/academia/related industries around the world

Cyberdyne Care Robotics
(Germany)

CYBERDYNE HQ

EMEA Base
Cyberdyne Care Robotics GmbH (Germany)

Cooperselios
(Italy)

PERKESO – REHABILITATION CENTRE MELALA
(Malaysia)

APAC Base
CYBERDYNE MALAYSIA SDN. BHD.

Singapore General Hospital
(Singapore)

RISE Healthcare Group
(USA California)

Brooks Rehabilitation
(US Florida)

Americas Base
CYBERDYNE USA INC.

EMEA : Europe, Middle East and Africa

Social implementation of Cybernics Treatment (Malaysia)

The National Center for Neuro-Robotics and Cybernics, the largest medical complex in Southeast Asia

PERKESO National Neuro-Robotic and Cybernics Rehab. Centre

- ✓ Construction underway in Ipoh, Perak, Northern part of Malaysia (Scheduled by the end of 2024)
- ✓ First phase project
  - ✓ 15.6 Hectare (Approx. 3.4 baseball stadiums)
  - ✓ Gross floor area is approximately 86,400 square meters
- ✓ Capable of accommodating 700 patients at any given time

Construction completed by 2024
Maximum number of units to be installed at a single facility (65 units)
Scheduled to officially open in 2025

Strategic base for social implementation of Cybernics Industry, such as HAL, Cybernics Products and technologies of other companies that CYBERDYNE invests through C-Startup

https://www.perkeso.gov.my/images/kenyataan_media/2023/190203_-_LAWATAN_MENTERI_SUMBER_MANUSIA_KE_TAPAK_PUSAT_REHABILITASI_PERKESO_PERAK.pdf?TSPD_101_R0=08e2dacd5fab2000f93a5be67765406ad4c598e4e5aedac205dcd286f8c106bc77d7648842ded7a008048fa483143000fbc3f707cd511bf1367c7352c9e10251d84d1723291abc11ccb8adcffc6ab4640a6f84d8e56752b87e7c10ac4d5baf7b

Social implementation of Cybernics Treatment (Malaysia)

Provides Cybernics Treatment free for patients due to Public Social Compensation Insurance

SOCSO/PERKESO (Malaysia Public Social Security Organization)

SOCSO has four functions: disability pension, survivor's pension, medical coverage and occupational injury coverage, and is compulsory for Malaysian and foreign workers in Malaysia to join the program. It provides medical compensation, disability compensation, funeral benefits, child support and nursing care benefits for illness or injury that occurs while commuting to and from work.

Facilities with HAL (14 facilities)

★ SOCSO/PERKESO Rehabilitation Center

Socso urged to build three new rehabilitation centres in five years

Bernama
15/01/2024 16:00 MYT

January 2024: The Minister of Human Resources requested the nationwide expansion of SOCSO (PERKESO) rehabilitation centers (three more locations, including Ipho, within five years).

https://www.astroawani.com/berita-malaysia/socso-urged-build-three-new-rehabilitation-centres-five-years-454129

Strategic Partnership Established to Promote Cybernics Medical and Healthcare Innovation in Japan and Taiwan

With Development Center for Biotechnology (DCB) and Fu Jen Catholic University

2025.3.4

(From left to right)
Fu Jen Catholic University Hospital
Prof. Dr. Horng-Huei Liou, Vice Superintendent

Development Center for Biotechnology
Dr. Michael Huang, Vice President

Fu Jen Catholic University
Prof. Francis Yi-Chen Lan, President

CYBERDYNE Inc.
Dr. Yoshiyuki Sankai, President and CEO

Center for Cybernics Research
Prof. Yoshihiro Kuroda, Director of Center

Global Expansion of Cybernics and Strengthening of International Collaboration (APAC)

Joint Promotion of Cybernics Medical and Healthcare Innovation with National Taiwan University

Signing of an International Memorandum of Understanding (MoU)
2025.6.18

Co-hosting of an International Symposium at NTU
2025.11.2

Opening remarks by President Wen-Chang Chen, NTU

Global Expansion of Cybernics and Strengthening of International Collaboration (EMEA)

HAL to be deployed through the Japan International Cooperation Agency (JICA) for Ukraine's reconstruction.

To be used for the treatment of people with disabilities caused by the war
HAL series 46 units, etc. Order amount: Approximately 360 million yen

Nov 19, 2024 Nikkei

ウクライナ復興に「HAL」

サイバーダイン 受注額3.6億円

装着型ロボット開発のCYBERDYNE（サイバーダイン）は18日、ウクライナに医療用サイボーグ型装着器具「HAL」を納入すると発表した。国際協力機構（JICA）による同国への復興支援の一環で受注額は約3億6000万円。ロシアとの戦禍で負傷した市民らの機能回復訓練に役立ててもらう。

JICAによるウクライナへのリハビリ機器や医療機器調達業務を受注したオガワ精機（東京・新宿）を通じ46台を納入する。下肢、腕や足の関節、腰のそれぞれの動きを支援する3機種が首都キーウの医療施設で活用されるという。サイバーダインは2025年3月期に売上高約2億5700万円、26年3月期に約1億3300万円を計上する。

医療用サイボーグ型装着器具「HAL」を戦禍で負傷した市民の身体機能回復訓練に役立てる

同社はHAL3タルで納海外展開る。ウク24年3月海外売上高める。

HALすためにす体電位信動くパワさは約3取り付け知した生蔵コンピし、装着る。

HAL経細胞の有効といどで改善とされた利用した動かなかで動き始がある」（

Disclaimer

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.